The Latest Breaking News from AstraZeneca

Families of people who died after taking Covid vaccine ‘ignored’ as zero compensation payouts made

More than 1,200 claims have been made to the government’s Vaccines Damages Payment Scheme, but no compensation has yet to be paid out

The Independent UK · Apr 30, 2022

48 Stocks Moving In Friday's Mid-Day Session

 Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS.

Benzinga · Apr 29, 2022

AstraZeneca boss calls for UK to provide new Covid-19 medicine to the vulnerable

Pharmaceutical CEO says it’s ‘sad’ that UK has failed to order Evusheld for the immunosuppressed

The Guardian - UK · Apr 29, 2022

Sales of Covid vaccine set to decline as demand wanes, AstraZeneca predicts

The business has already seen a significant drop in the use of its vaccines to Europe.

The Independent UK · Apr 29, 2022

How To Attend AstraZeneca Q1 2022 Earnings Conference Call

  AstraZeneca (NASDAQ:AZN) will host a conference call at 06:45 AM ET on April 29, 2022, to discuss Q1 2022 earnings results. How to Attend AstraZeneca (AZN) Conference Call Follow this link to access the live webcast.

Benzinga · Apr 25, 2022

Latest data shows significant rise in Covid deaths in England and Wales for third week in a row

Deaths involving Covid-19 are up 13 per cent on last week, the latest data shows

Manchester Evening News · Apr 21, 2022

If You Invested $100 In AstraZeneca 5 Years Ago, Here's How Much You Would Have Today

AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 4.24% on an annualized basis producing an average annual return of 17.72%. Currently, AstraZeneca has a market capitalization of $213.61 billion.

Benzinga · Apr 21, 2022

Covid booster gives long-lasting protection, study finds

'The longer-term protection against hospitalisation and death is perhaps the most important factor for future booster programmes'

Wales Online · Apr 21, 2022

Third Covid-19 vaccine dose offers ‘prolonged immune response’ – UK-wide study

The study compared immune responses to seven vaccines used as a booster 28 days after two initial doses.

The Independent UK · Apr 21, 2022

AstraZeneca's COVID-19 Antibody Provides Protection For At Least Six Months In High-Risk Individuals

AstraZeneca plc (NASDAQ:AZN) shared detailed results from the PROVENT Phase 3 pre-exposure prophylaxis (prevention) trial of Evusheld (tixagevimab and cilgavimab), formerly AZD7442. The data showed that Evusheld reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and 83% in the six-month follow-up analysis, compared to placebo.  There were no…

Benzinga · Apr 21, 2022